Cargando…

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer

Current Therapeutic modalities provide no survival advantage to gastric cancer (GC) patients. Targeting the human epidermal growth factor receptor-2 (HER-2) is a viable therapeutic strategy against advanced HER-2 positive GC. Antibody-drug conjugates, small-molecule tyrosine kinase inhibitors (TKIs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Jiangang, Li, Xiaojing, Chen, Peng, Gao, Yongshun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304417/ https://www.ncbi.nlm.nih.gov/pubmed/35873388 http://dx.doi.org/10.2147/JIR.S368138

Ejemplares similares

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

Down-Regulation of USP8 Suppresses HER-3 Positive Gastric Cancer Cells Proliferation
por: Sun, Jiangang, et al.
Publicado: (2020)

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
por: Gómez-Martin, Carlos, et al.
Publicado: (2012)

USP8 Inhibitor Suppresses HER-2 Positive Gastric Cancer Cell Proliferation and Metastasis via the PI3K/AKT Signaling Pathway
por: Sun, Jiangang, et al.
Publicado: (2020)

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
por: de Melo Gagliato, Debora, et al.
Publicado: (2016)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Oncogenic HER2 fusions in gastric cancer
por: Yu, De-Hua, et al.
Publicado: (2015)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

Contextual reprogramming of CAR-T cells for treatment of HER2(+) cancers
por: Yang, Zhifen, et al.
Publicado: (2021)

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis
por: Zhou, Chenfei, et al.
Publicado: (2018)

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
por: Novillo, Apolonia, et al.
Publicado: (2023)

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
por: Pous, Anna, et al.
Publicado: (2023)

Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
por: Huang, Le-Tian, et al.
Publicado: (2019)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Mouse models and anti-HER2 therapies
por: Hanker, Ariella B., et al.
Publicado: (2013)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
por: Wang, Jin, et al.
Publicado: (2023)

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
por: Strasser-Weippl, Kathrin, et al.
Publicado: (2015)

Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
por: Kim, H, et al.
Publicado: (2016)

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
por: Smith, Alison E., et al.
Publicado: (2021)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
por: You, Ji Young, et al.
Publicado: (2023)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
por: Batalha, Sofia, et al.
Publicado: (2023)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
por: Liu, Yunhua, et al.
Publicado: (2018)

The application of HER2 and CD47 CAR-macrophage in ovarian cancer
por: Chen, Yizhao, et al.
Publicado: (2023)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
por: Muntasell, Aura, et al.
Publicado: (2017)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
por: Weisser, Nina E., et al.
Publicado: (2023)

Anti-HER2 imaging agents for breast cancer imaging
por: Tolner, B, et al.
Publicado: (2010)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_esi3mc80anslp1a5g97s30hhcd